NEJM Evidence
Q1 Journal
Journal
Country
United States
Northern America
Subject Area and Category
Medicine
└
Drug Discovery
Q1
└
Medicine (miscellaneous)
Q1
└
Pharmacology
Q1
Publisher
SJR 2025
3.979
Q1
SJR Score
H-Index
19
Citations / Doc (2yr)
6.20
Total Docs. (latest)
81
Total Citations (3yr)
921
Publication type
Journals
ISSN
27665526
Coverage
2022-2025
Journal Rank
#439
Subject Categories
Drug Discovery
Q1
Medicine (miscellaneous)
Q1
Pharmacology
Q1
Subject Areas
Aims & Scope
The volume of clinical research continues to grow, yet the standards to establish and validate claims, especially as related to clinical practice, have not followed suit.
NEJM Evidence expands the corpus of published research with a focus on providing more context and critical evaluation of the methods and results to support clinical decision-making and does so in a way that respects the time and commitment of the practitioner.
NEJM Evidence seeks to advance clinical trial research and clinical practice by:
• Publishing high-quality studies from the front lines of medical research.
• Challenging the medical community to take new approaches to clinical trial design and execution that yield more powerful clinical evidence.
• Sparking debate and conversation around areas of medicine where clinical decisions are made without sufficient evidence.
• Engaging physicians in a more sophisticated and meaningful way with clinical evidence.
Abstracting & Indexing
Scopus
Google Scholar
Medline
Detailed Metrics
| Total Docs. (latest) | 81 |
| Total Docs. (3 years) | 149 |
| Total Refs. | 1,719 |
| Total Citations (3 years) | 921 |
| Citable Docs. (3 years) | 91 |
| Citations / Doc. (2 years) | 6.20 |
| Ref. / Doc. | 21.22 |
| % Female | 41.1% |
Metrics Visualization
Latest year data vs 3-year cumulative figures
Publication & Citation Trend
Loading trend data from Crossref...
Top 10 Most Cited Articles
Loading articles...
Researcher Reviews
Write a ReviewNo reviews yet for this journal.
Be the first to share your experience!
Share Your Experience
Your review will be published after moderation. Email will not be displayed publicly.